The Path Forward to Biomarker Discovery in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 434-436 ◽  
Author(s):  
DAFNA D. GLADMAN ◽  
CHRISTOPHER T. RITCHLIN ◽  
OLIVER FITZGERALD
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Radiographic Progression ◽  
Biomarker Discovery ◽  
Clinical Phenotype ◽  
Inception Cohort ◽  
Psoriatic Disease ◽  
Definition Of ◽  
Biomarker Research

At the 2010 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), wide-ranging discussions were held regarding biomarker research in psoriatic disease. Consensus was reached on 2 areas of priority: (1) the study of soluble biomarkers of radiographic progression in psoriatic arthritis (PsA); and (2) the analysis of comorbidity biomarkers, specifically cardiovascular and articular, in a psoriasis inception cohort. For each of these areas, rigorous definition of the clinical phenotype of PsA will be essential. To date, 2 instruments have been identified to define the phenotype: the ClASsification of Psoriatic ARthritis criteria and various screening questionnaires. In this overview, we discuss the challenges of the clinical phenotype of PsA and review GRAPPA plans for developing a research program for biomarker discovery.

Prologue: 2010 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

2012 ◽  
Vol 39 (2) ◽  
pp. 391-393 ◽  
Author(s):  
PHILIP J. MEASE ◽  
DAFNA D. GLADMAN
Keyword(s):  
Psoriatic Arthritis ◽  
Global Education ◽  
Training Session ◽  
Original Research ◽  
Psoriatic Disease ◽  
Composite Measures ◽  
The Status ◽  
Patient Groups ◽  
Definition Of ◽  
Biomarker Research

The 2010 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in December 2010 in Miami Beach, Florida, USA, with attendance by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups. In a training session that preceded the GRAPPA meeting, members served as faculty while rheumatology fellows and dermatology residents presented their original research. During the 2-day GRAPPA meeting, presentations included a review of composite measures for psoriatic arthritis (PsA) and psoriasis, updates on imaging in psoriatic disease (ultrasound and magnetic resonance imaging), a 3-part discussion of the definition of inflammatory musculoskeletal disease, a 4-part discussion of the status and path forward in psoriatic disease biomarker research, an update on comorbidities in psoriasis and PsA, and a review of global education and partnering opportunities. Introductions to the discussions at the GRAPPA 2010 meeting are included in this prologue.

Biomarkers of Radiographic Progression in Psoriatic Arthritis: A Report from the GRAPPA 2011 Annual Meeting

2012 ◽  
Vol 39 (11) ◽  
pp. 2189-2192 ◽  
Author(s):  
OLIVER FITZGERALD ◽  
CHRISTOPHER T. RITCHLIN ◽  
PHILIP J. MEASE
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Structural Damage ◽  
Radiographic Progression ◽  
Clinical Markers ◽  
Sample Collection ◽  
Critical Research ◽  
Specific Protocol ◽  
Radiographic Scoring Methods ◽  
Selection Of

Clinical markers of radiographic progression have been studied in patients with psoriatic arthritis (PsA), and results have clearly confirmed the progression of radiographic damage over a 2-year period. Biomarkers of radiographic progression damage (erosion and new bone formation) have also been identified as a critical research issue in these patients. At the 2011 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members discussed development of a pivotal observational study (PsA Biodam study) to determine the validity of several soluble biomarkers in predicting structural damage in patients with PsA receiving standard therapies. Specific protocol issues discussed were the inclusion criteria, selection of candidate biomarkers, timing of sample collection, the primary radiographic outcome measure, radiographic scoring methods, possible substudies, and funding strategies.

Psoriasis and Psoriatic Arthritis in the Context of the COVID-19 Pandemic: A Plenary Session From the GRAPPA 2020 Annual Meeting

2021 ◽  
pp. jrheum.201671
Author(s):  
Philip J. Mease ◽  
Leonard H. Calabrese ◽  
Kristina Callis Duffin ◽  
Rebecca H. Haberman ◽  
Rodrigo Firmino ◽  
...  
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Severe Disease ◽  
Vaccine Safety ◽  
Global Scale ◽  
Disease Course ◽  
Risk Of Infection ◽  
Psoriatic Disease ◽  
Increased Risk ◽  
Infectious Disease Specialists

The coronavirus disease 2019 (COVID-19; caused by SARS-CoV-2) pandemic has affected the healthcare system on a global scale, and we utilized the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) 2020 annual meeting to examine how COVID-19 might affect patients with psoriatic disease (PsD) and the clinicians who care for them. Pressing issues and concerns identified included whether having psoriasis increased the risk of acquiring COVID-19, vaccine safety, and the acceptability of telehealth. The general message from rheumatologists, dermatologists, infectious disease specialists, and patient research partners was that data did not suggest that having PsD or its treatment significantly increased risk of infection or more severe disease course, and that the telehealth experience was a success overall.

scholarly journals The Potential of Metabolomics in the Diagnosis of Thyroid Cancer

2020 ◽  
Vol 21 (15) ◽  
pp. 5272
Author(s):  
Margarida Coelho ◽  
Luis Raposo ◽  
Brian J. Goodfellow ◽  
Luigi Atzori ◽  
John Jones ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Biomarker Discovery ◽  
Endocrine System ◽  
Final Diagnosis ◽  
Needle Aspiration ◽  
Pathological Conditions ◽  
Biomarker Research ◽  
Diagnosis Of Thyroid Cancer ◽  
Personalised Therapy

Thyroid cancer is the most common endocrine system malignancy. However, there is still a lack of reliable and specific markers for the detection and staging of this disease. Fine needle aspiration biopsy is the current gold standard for diagnosis of thyroid cancer, but drawbacks to this technique include indeterminate results or an inability to discriminate different carcinomas, thereby requiring additional surgical procedures to obtain a final diagnosis. It is, therefore, necessary to seek more reliable markers to complement and improve current methods. “Omics” approaches have gained much attention in the last decade in the field of biomarker discovery for diagnostic and prognostic characterisation of various pathophysiological conditions. Metabolomics, in particular, has the potential to identify molecular markers of thyroid cancer and identify novel metabolic profiles of the disease, which can, in turn, help in the classification of pathological conditions and lead to a more personalised therapy, assisting in the diagnosis and in the prediction of cancer behaviour. This review considers the current results in thyroid cancer biomarker research with a focus on metabolomics.

Strategies for Biomarker Development in Psoriatic Disease: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 423-426 ◽  
Author(s):  
CHRISTOPHER T. RITCHLIN
Keyword(s):  
Cardiovascular Disease ◽  
Metabolic Syndrome ◽  
Psoriatic Arthritis ◽  
Psoriatic Disease ◽  
Funding Sources ◽  
Inflammatory Bowel ◽  
Biomarker Research ◽  
Anxiety Depression ◽  
Collaborative Efforts ◽  
Musculoskeletal Involvement

Psoriatic disease includes psoriasis and associated comorbidities (arthritis, uveitis, inflammatory bowel disease, cardiovascular disease, metabolic syndrome, and anxiety/depression) and is remarkably diverse in disease presentation and course. The marked heterogeneity of musculoskeletal involvement in psoriatic arthritis (PsA) presents major challenges to clinicians regarding diagnosis, risk stratification, and management. Members of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) have begun collaborative efforts to develop biomarkers that can assist in the diagnosis and management of patients with psoriasis and related comorbidities. This brief review provides a rationale for biomarker research in PsA, consideration of types and sources of biomarkers, and examples of important biomarker studies in PsA, followed by a review of trial designs for biomarker research and a discussion of potential funding sources.

Arthritis Mutilans: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1419-1422 ◽  
Author(s):  
Vinod Chandran ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell ◽  
Björn Gudbjörnsson
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Clinical Features ◽  
Severe Form ◽  
Group Discussions ◽  
Epidemiological Research ◽  
Breakout Group ◽  
Definition Of ◽  
Arthritis Mutilans ◽  
Broad Consensus

Arthritis mutilans is often described as the most severe form of psoriatic arthritis. However, a widely agreed on definition of the disease has not been developed. At the 2012 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA), members hoped to agree on a definition of arthritis mutilans and thus facilitate clinical and molecular epidemiological research into the disease. Members discussed the clinical features of arthritis mutilans and definitions used by researchers to date; reviewed data from the ClASsification for Psoriatic ARthritis study, the Nordic psoriatic arthritis mutilans study, and the results of a premeeting survey; and participated in breakout group discussions. Through this exercise, GRAPPA members developed a broad consensus on the features of arthritis mutilans, which will help us develop a GRAPPA-endorsed definition of arthritis mutilans.

scholarly journals GRAPPA Trainees Symposium 2013: A Report from the GRAPPA 2013 Annual Meeting

2014 ◽  
Vol 41 (6) ◽  
pp. 1200-1205 ◽  
Author(s):  
Agnes Szentpetery ◽  
Mary Ann N. Johnson ◽  
Christopher T. Ritchlin
Keyword(s):  
Psoriatic Arthritis ◽  
Clinical Research ◽  
Annual Meeting ◽  
Psoriatic Disease ◽  
The World ◽  
Oral Presentations

At the 2013 annual meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) in Toronto, Ontario, Canada, 26 dermatology and rheumatology fellows engaged in psoriasis or psoriatic arthritis research were invited to present their work at the Trainees Symposium, which preceded the annual meeting and was also attended by GRAPPA members from around the world. Herein, we provide a brief overview of the 6 oral presentations and 25 posters presented, which reflect the focus and diversity of current basic and clinical research in psoriatic disease.

GRAPPA Trainees Symposium 2010: A Report from the GRAPPA 2010 Annual Meeting

2012 ◽  
Vol 39 (2) ◽  
pp. 394-397 ◽  
Author(s):  
CHRISTOPHER T. RITCHLIN
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Psoriatic Disease ◽  
Oral Presentations

At the 2010 annual meeting of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), 24 trainees (rheumatology fellows and dermatology residents) engaged in research in psoriatic disease were invited to present their work at the Trainees Symposium, which preceded the GRAPPA meeting and was also attended by GRAPPA members and invited guests. Nineteen posters and 6 oral presentations were presented by the trainees, all of which are summarized here.

Prologue: 2011 Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)

2012 ◽  
Vol 39 (11) ◽  
pp. 2181-2183 ◽  
Author(s):  
PHILIP J. MEASE ◽  
DAFNA D. GLADMAN
Keyword(s):  
Psoriatic Arthritis ◽  
Global Education ◽  
Aboriginal People ◽  
Research Work ◽  
Original Research ◽  
Disease Biomarker ◽  
Psoriatic Disease ◽  
The Status ◽  
Patient Groups ◽  
Biomarker Research

The 2011 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) was held in July 2011 in Naples, Italy, and attended by rheumatologists, dermatologists, and representatives of biopharmaceutical companies and patient groups from around the world. The meeting began with a trainee symposium, where 25 rheumatology fellows and dermatology residents presented their original research work. Presentations and discussions by GRAPPA members during the remaining 2-day meeting included a 2-part discussion of the status of psoriatic disease biomarker research, summaries of the GRAPPA Composite Exercise and the GRAPPA video projects, a contribution from Italian members on their psoriasis and PsA projects, a lengthy discussion of research and collaborative initiatives from GRAPPA dermatologists, updates on ultrasound imaging in psoriatic disease and on plans to define inflammatory musculoskeletal disease, a presentation of the results of a small study of psoriasis and PsA in aboriginal people of Peru, and a review of global education and partnering opportunities. Introductions to these discussions are included in this prologue.

Development of Simple Clinical Criteria for the Definition of Inflammatory Arthritis, Enthesitis, Dactylitis, and Spondylitis: A Report from the GRAPPA 2012 Annual Meeting

2013 ◽  
Vol 40 (8) ◽  
pp. 1442-1445 ◽  
Author(s):  
Philip J. Mease ◽  
Amit Garg ◽  
Dafna D. Gladman ◽  
Philip S. Helliwell
Keyword(s):  
Psoriatic Arthritis ◽  
Annual Meeting ◽  
Inflammatory Disease ◽  
Inflammatory Arthritis ◽  
Nominal Group Technique ◽  
Nominal Group ◽  
Clinical Criteria ◽  
Expert Clinician ◽  
Primary Care Clinicians ◽  
Definition Of

Dermatologist and primary care clinicians are in an ideal position to identify the emergence of psoriatic arthritis (PsA) in patients with psoriasis. Yet these clinicians are not well trained to distinguish inflammatory musculoskeletal disease from other more common problems such as osteoarthritis, traumatic or degenerative tendonitis and back pain, or fibromyalgia. A simple set of clinical criteria to identify inflammatory disease would aid recognition of PsA. At its 2012 annual meeting, the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) discussed development of evidence-based, practical, and reliable definitions of inflammatory arthritis, enthesitis, dactylitis, and spondylitis. This project will be a sequential process of expert clinician nominal-group technique, patient surveys and focus groups, and Delphi exercises to identify core features of inflammatory disease, testing these in a small group of patients with and without inflammatory disease, and finally validating these criteria in larger groups of patients.

Sign in / Sign up

Export Citation Format

Share Document